In animal models of obesity and diabetes [38], [39], [40] as well as in obese subjects [41], [42], treatment with CB1R antagonists such as rimonabant has led to increased plasma adiponectin level, in particular the high molecular weight adiponectin. Here, ADIPOQ is linked to obesity disorder.